Skip to main content

Table 1 Demographic and clinical characteristics of patients with SSc enrolled in the study

From: Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression

Characteristic Value
Age (years), mean (SD) 44.6 (15.4)
Age (years), median (range) 46.0 (20.0–67.0)
Female, number (%) 24 (85.7)
Male, number (%) 4 (14.3)
Disease duration (months), mean (SD) 44.7 (71.5)
Disease duration (months), median (range) 16.00 (3–360)
Early disease, number (%) 19 (67.9)
Long-standing disease, number (%) 9 (32.1)
Anti-Scl-70 positivity, number (%) 21 (75.0)
ACA positivity, number (%) 3 (10.7)
RNA polymerase III positivity, number (%) 1 (3.6)
ANA positivitya, number (%) 3 (10.7)
dSSc, number (%) 20 (71.4)
lSSc, number (%) 8 (28.6)
Skin score, mean (SD) 15.8 (11.3)
Skin score, median (range) 14.0 (2.0–43.0)
Activity index, mean (SD) 4.4 (2.0)
Activity index, median (range) 4.2 (1.0–8.5)
Severity index, mean (SD) 8.0 (2.6)
Severity index, median (range) 7.5 (4.0–14.0)
FVC (%), mean (SD) 87.8 ± 22.1
FVC (%), median (range) 94.0 (41.0–123.0)
DLCO (%), mean (SD) 57.3 ± 18.4
DLCO (%), median (range) 57.0 (26.0–93.0)
HRCT interstitial score, mean (SD) 7.6 (2.3)
HRCT interstitial score, median (range) 7.0 (4.0–14.0)
HRCT alveolar score, mean (SD) 6.7 (5.0)
HRCT alveolar score, median (range) 6.0 (0.0–16)
ESR, mm/h, mean (SD) 20.4 (20.3)
ESR, median (range) 12.0 (2.0–84.0)
  1. The values are indicated as the mean (SD) and median (range) or number (percentage)
  2. ANA antinuclear antibodies, ACA anticentromere antibodies, anti-Scl-70 anti-topoisomerase antibodies, dSSc diffuse skin disease, lSSc limited skin disease, FVC forced vital capacity, DLCO diffusion lung carbon monoxide, ESR erythrocyte sedimentation rate
  3. aANA positivity: two patients who were ANA-positive presented with a homogeneous pattern, and one patient presented with a nucleolar pattern